NCT06450041 2025-11-04NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialNew Approaches to Neuroblastoma Therapy ConsortiumPhase 2 Recruiting62 enrolled